Orthocell has finalised a move to boost its stake in Marine Biomedical, the company developing a bone substitute using Kimberley pearls, simultaneously securing global distribution rights.

Orthocell has finalised a move to boost its stake in Marine Biomedical, the company developing a bone substitute using Kimberley pearls, simultaneously securing global distribution rights.